Search

Your search keyword '"Tillner, Joachim"' showing total 25 results
Start Over Author "Tillner, Joachim"
25 results on '"Tillner, Joachim"'

1. Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration

Author

Jennison, Christopher, Ehrhardt, Beate, Baum, Patrick, Schoelsch, Corinna, Freijer, Jan, Grempler, Rolf, Graefe-Mody, Ulrike, Hennige, Anita, Dings, Christiane, Lehr, Thorsten, Scherer, Nina, Sihinecich, Iryna, Pattou, Francois, Raverdi, Violeta, Caiazzo, Robert, Torres, Fanelly, Verkindt, Helene, Mari, Andrea, Tura, Andrea, Giorgino, Toni, Bizzotto, Roberto, Froguel, Philippe, Bonneford, Amelie, Canouil, Mickael, Dhennin, Veronique, Brorsson, Caroline, Brunak, Soren, De Masi, Federico, Gudmundsdóttir, Valborg, Pedersen, Helle, Banasik, Karina, Thomas, Cecilia, Sackett, Peter, Staerfeldt, Hans-Henrik, Lundgaard, Agnete, Nilsson, Birgitte, Nielsen, Agnes, Mazzoni, Gianluca, Karaderi, Tugce, Rasmussen, Simon, Johansen, Joachim, Allesøe, Rosa, Fritsche, Andreas, Thorand, Barbara, Adamski, Jurek, Grallert, Harald, Haid, Mark, Sharma, Sapna, Troll, Martina, Adam, Jonathan, Ferrer, Jorge, Eriksen, Heather, Frost, Gary, Haussler, Ragna, Hong, Mun-gwan, Schwenk, Jochen, Uhlen, Mathias, Nicolay, Claudia, Pavo, Imre, Steckel-Hamann, Birgit, Thomas, Melissa, Adragni, Kofi, Wu, Han, Hart, Leen't, Roderick, Slieker, van Leeuwen, Nienke, Dekkers, Koen, Frau, Francesca, Gassenhuber, Johann, Jablonka, Bernd, Musholt, Petra, Ruetten, Hartmut, Tillner, Joachim, Baltauss, Tania, Bernard Poenaru, Oana, de Preville, Nathalie, Rodriquez, Marianne, Arumugam, Manimozhiyan, Allin, Kristine, Engelbrechtsen, Line, Hansen, Torben, Hansen, Tue, Forman, Annemette, Jonsson, Anna, Pedersen, Oluf, Dutta, Avirup, Vogt, Josef, Vestergaard, Henrik, Laakso, Markku, Kokkola, Tarja, Kuulasmaa, Teemu, Franks, Paul, Giordano, Nick, Pomares-Millan, Hugo, Fitipaldi, Hugo, Mutie, Pascal, Klintenberg, Maria, Bergstrom, Margit, Groop, Leif, Ridderstrale, Martin, Atabaki Pasdar, Naeimeh, Deshmukh, Harshal, Heggie, Alison, Wake, Dianne, McEvoy, Donna, McVittie, Ian, Walker, Mark, Hattersley, Andrew, Hill, Anita, Jones, Angus, McDonald, Timothy, Perry, Mandy, Nice, Rachel, Hudson, Michelle, Thorne, Claire, Dermitzakis, Emmanouil, Viñuela, Ana, Cabrelli, Louise, Loftus, Heather, Dawed, Adem, Donnelly, Louise, Forgie, Ian, Pearson, Ewan, Palmer, Colin, Brown, Andrew, Koivula, Robert, Wesolowska-Andersen, Agata, Abdalla, Moustafa, McRobert, Nicky, Fernandez, Juan, Jiao, Yunlong, Robertson, Neil, Gough, Stephen, Kaye, Jane, Mourby, Miranda, Mahajan, Anubha, McCarthy, Mark, Shah, Nisha, Teare, Harriet, Holl, Reinhard, Koopman, Anitra, Rutters, Femke, Beulens, Joline, Groeneveld, Lenka, Bell, Jimmy, Thomas, Louise, Whitcher, Brandon, Wilman, Henry R., Parisinos, Constantinos A., Atabaki-Pasdar, Naeimeh, Kelly, Matt, Thomas, E. Louise, Neubauer, Stefan, Hingorani, Aroon D., Patel, Riyaz S., Hemingway, Harry, Franks, Paul W., Bell, Jimmy D., Banerjee, Rajarshi, and Yaghootkar, Hanieh

Published
2019
Full Text
View/download PDF

3. Discovery of drug–omics associations in type 2 diabetes with generative deep-learning models

Author

Allesøe, Rosa Lundbye, Lundgaard, Agnete Troen, Hernández Medina, Ricardo, Aguayo-Orozco, Alejandro, Johansen, Joachim, Nissen, Jakob Nybo, Brorsson, Caroline, Mazzoni, Gianluca, Niu, Lili, Biel, Jorge Hernansanz, Brasas, Valentas, Webel, Henry, Benros, Michael Eriksen, Pedersen, Anders Gorm, Chmura, Piotr Jaroslaw, Jacobsen, Ulrik Plesner, Mari, Andrea, Koivula, Robert, Mahajan, Anubha, Vinuela, Ana, Tajes, Juan Fernandez, Sharma, Sapna, Haid, Mark, Hong, Mun-Gwan, Musholt, Petra B., De Masi, Federico, Vogt, Josef, Pedersen, Helle Krogh, Gudmundsdottir, Valborg, Jones, Angus, Kennedy, Gwen, Bell, Jimmy, Thomas, E. Louise, Frost, Gary, Thomsen, Henrik, Hansen, Elizaveta, Hansen, Tue Haldor, Vestergaard, Henrik, Muilwijk, Mirthe, Blom, Marieke T., ‘t Hart, Leen M., Pattou, Francois, Raverdy, Violeta, Brage, Soren, Kokkola, Tarja, Heggie, Alison, McEvoy, Donna, Mourby, Miranda, Kaye, Jane, Hattersley, Andrew, McDonald, Timothy, Ridderstråle, Martin, Walker, Mark, Forgie, Ian, Giordano, Giuseppe N., Pavo, Imre, Ruetten, Hartmut, Pedersen, Oluf, Hansen, Torben, Dermitzakis, Emmanouil, Franks, Paul W., Schwenk, Jochen M., Adamski, Jerzy, McCarthy, Mark I., Pearson, Ewan, Banasik, Karina, Rasmussen, Simon, Brunak, Søren, Froguel, Philippe, Thomas, Cecilia Engel, Häussler, Ragna S., Beulens, Joline, Rutters, Femke, Nijpels, Giel, van Oort, Sabine, Groeneveld, Lenka, Elders, Petra, Giorgino, Toni, Rodriquez, Marianne, Nice, Rachel, Perry, Mandy, Bianzano, Susanna, Graefe-Mody, Ulrike, Hennige, Anita, Grempler, Rolf, Baum, Patrick, Stærfeldt, Hans Henrik, Shah, Nisha, Teare, Harriet, Ehrhardt, Beate, Tillner, Joachim, Dings, Christiane, Lehr, Thorsten, Scherer, Nina, Sihinevich, Iryna, Cabrelli, Louise, Loftus, Heather, Bizzotto, Roberto, Tura, Andrea, Dekkers, Koen, Allesøe, Rosa Lundbye, Lundgaard, Agnete Troen, Hernández Medina, Ricardo, Aguayo-Orozco, Alejandro, Johansen, Joachim, Nissen, Jakob Nybo, Brorsson, Caroline, Mazzoni, Gianluca, Niu, Lili, Biel, Jorge Hernansanz, Brasas, Valentas, Webel, Henry, Benros, Michael Eriksen, Pedersen, Anders Gorm, Chmura, Piotr Jaroslaw, Jacobsen, Ulrik Plesner, Mari, Andrea, Koivula, Robert, Mahajan, Anubha, Vinuela, Ana, Tajes, Juan Fernandez, Sharma, Sapna, Haid, Mark, Hong, Mun-Gwan, Musholt, Petra B., De Masi, Federico, Vogt, Josef, Pedersen, Helle Krogh, Gudmundsdottir, Valborg, Jones, Angus, Kennedy, Gwen, Bell, Jimmy, Thomas, E. Louise, Frost, Gary, Thomsen, Henrik, Hansen, Elizaveta, Hansen, Tue Haldor, Vestergaard, Henrik, Muilwijk, Mirthe, Blom, Marieke T., ‘t Hart, Leen M., Pattou, Francois, Raverdy, Violeta, Brage, Soren, Kokkola, Tarja, Heggie, Alison, McEvoy, Donna, Mourby, Miranda, Kaye, Jane, Hattersley, Andrew, McDonald, Timothy, Ridderstråle, Martin, Walker, Mark, Forgie, Ian, Giordano, Giuseppe N., Pavo, Imre, Ruetten, Hartmut, Pedersen, Oluf, Hansen, Torben, Dermitzakis, Emmanouil, Franks, Paul W., Schwenk, Jochen M., Adamski, Jerzy, McCarthy, Mark I., Pearson, Ewan, Banasik, Karina, Rasmussen, Simon, Brunak, Søren, Froguel, Philippe, Thomas, Cecilia Engel, Häussler, Ragna S., Beulens, Joline, Rutters, Femke, Nijpels, Giel, van Oort, Sabine, Groeneveld, Lenka, Elders, Petra, Giorgino, Toni, Rodriquez, Marianne, Nice, Rachel, Perry, Mandy, Bianzano, Susanna, Graefe-Mody, Ulrike, Hennige, Anita, Grempler, Rolf, Baum, Patrick, Stærfeldt, Hans Henrik, Shah, Nisha, Teare, Harriet, Ehrhardt, Beate, Tillner, Joachim, Dings, Christiane, Lehr, Thorsten, Scherer, Nina, Sihinevich, Iryna, Cabrelli, Louise, Loftus, Heather, Bizzotto, Roberto, Tura, Andrea, and Dekkers, Koen

Abstract

The application of multiple omics technologies in biomedical cohorts has the potential to reveal patient-level disease characteristics and individualized response to treatment. However, the scale and heterogeneous nature of multi-modal data makes integration and inference a non-trivial task. We developed a deep-learning-based framework, multi-omics variational autoencoders (MOVE), to integrate such data and applied it to a cohort of 789 people with newly diagnosed type 2 diabetes with deep multi-omics phenotyping from the DIRECT consortium. Using in silico perturbations, we identified drug–omics associations across the multi-modal datasets for the 20 most prevalent drugs given to people with type 2 diabetes with substantially higher sensitivity than univariate statistical tests. From these, we among others, identified novel associations between metformin and the gut microbiota as well as opposite molecular responses for the two statins, simvastatin and atorvastatin. We used the associations to quantify drug–drug similarities, assess the degree of polypharmacy and conclude that drug effects are distributed across the multi-omics modalities., Correction in DOI 10.1038/s41587-023-01805-9QC 20230626

Published
2023
Full Text
View/download PDF

4. Genetic analysis of blood molecular phenotypes reveals common properties in the regulatory networks affecting complex traits

Author

Brown, Andrew A., Fernandez-Tajes, Juan J., Hong, Mun gwan, Brorsson, Caroline A., Koivula, Robert W., Davtian, David, Dupuis, Théo, Sartori, Ambra, Michalettou, Theodora Dafni, Forgie, Ian M., Adam, Jonathan, Allin, Kristine H., Caiazzo, Robert, Cederberg, Henna, De Masi, Federico, Elders, Petra J.M., Giordano, Giuseppe N., Haid, Mark, Hansen, Torben, Hansen, Tue H., Hattersley, Andrew T., Heggie, Alison J., Howald, Cédric, Jones, Angus G., Kokkola, Tarja, Laakso, Markku, Mahajan, Anubha, Mari, Andrea, McDonald, Timothy J., McEvoy, Donna, Mourby, Miranda, Musholt, Petra B., Nilsson, Birgitte, Pattou, Francois, Penet, Deborah, Raverdy, Violeta, Ridderstråle, Martin, Romano, Luciana, Rutters, Femke, Sharma, Sapna, Teare, Harriet, ‘t Hart, Leen, Tsirigos, Konstantinos D., Vangipurapu, Jagadish, Vestergaard, Henrik, Brunak, Søren, Franks, Paul W., Frost, Gary, Grallert, Harald, Jablonka, Bernd, McCarthy, Mark I., Pavo, Imre, Pedersen, Oluf, Ruetten, Hartmut, Walker, Mark, Adragni, Kofi, Allesøe, Rosa Lundbye L., Artati, Anna A., Arumugam, Manimozhiyan, Atabaki-Pasdar, Naeimeh, Baltauss, Tania, Banasik, Karina, Barnett, Anna L., Baum, Patrick, Bell, Jimmy D., Beulens, Joline W., Bianzano, Susanna B., Bizzotto, Roberto, Bonnefond, Amelie, Cabrelli, Louise, Dale, Matilda, Dawed, Adem Y., de Preville, Nathalie, Dekkers, Koen F., Deshmukh, Harshal A., Dings, Christiane, Donnelly, Louise, Dutta, Avirup, Ehrhardt, Beate, Engelbrechtsen, Line, Eriksen, Rebeca, Fan, Yong, Ferrer, Jorge, Fitipaldi, Hugo, Forman, Annemette, Fritsche, Andreas, Froguel, Philippe, Gassenhuber, Johann, Gough, Stephen, Graefe-Mody, Ulrike, Grempler, Rolf, Groeneveld, Lenka, Groop, Leif, Gudmundsdóttir, Valborg, Gupta, Ramneek, Hennige, Anita M.H., Hill, Anita V., Holl, Reinhard W., Hudson, Michelle, Jacobsen, Ulrik Plesner, Jennison, Christopher, Johansen, Joachim, Jonsson, Anna, Karaderi, Tugce, Kaye, Jane, Kennedy, Gwen, Klintenberg, Maria, Kuulasmaa, Teemu, Lehr, Thorsten, Loftus, Heather, Lundgaard, Agnete Troen T., Mazzoni, Gianluca, McRobert, Nicky, McVittie, Ian, Nice, Rachel, Nicolay, Claudia, Nijpels, Giel, Palmer, Colin N., Pedersen, Helle K., Perry, Mandy H., Pomares-Millan, Hugo, Prehn, Cornelia P., Ramisch, Anna, Rasmussen, Simon, Robertson, Neil, Rodriquez, Marianne, Sackett, Peter, Scherer, Nina, Shah, Nisha, Sihinevich, Iryna, Slieker, Roderick C., Sondertoft, Nadja B., Steckel-Hamann, Birgit, Thomas, Melissa K., Thomas, Cecilia Engel E., Thomas, Elizabeth Louise L., Thorand, Barbara, Thorne, Claire E., Tillner, Joachim, Tura, Andrea, Uhlen, Mathias, van Leeuwen, Nienke, van Oort, Sabine, Verkindt, Helene, Vogt, Josef, Wad Sackett, Peter W., Wesolowska-Andersen, Agata, Whitcher, Brandon, White, Margaret W., Adamski, Jerzy, Schwenk, Jochen M., Pearson, Ewan R., Dermitzakis, Emmanouil T., Viñuela, Ana, Brown, Andrew A., Fernandez-Tajes, Juan J., Hong, Mun gwan, Brorsson, Caroline A., Koivula, Robert W., Davtian, David, Dupuis, Théo, Sartori, Ambra, Michalettou, Theodora Dafni, Forgie, Ian M., Adam, Jonathan, Allin, Kristine H., Caiazzo, Robert, Cederberg, Henna, De Masi, Federico, Elders, Petra J.M., Giordano, Giuseppe N., Haid, Mark, Hansen, Torben, Hansen, Tue H., Hattersley, Andrew T., Heggie, Alison J., Howald, Cédric, Jones, Angus G., Kokkola, Tarja, Laakso, Markku, Mahajan, Anubha, Mari, Andrea, McDonald, Timothy J., McEvoy, Donna, Mourby, Miranda, Musholt, Petra B., Nilsson, Birgitte, Pattou, Francois, Penet, Deborah, Raverdy, Violeta, Ridderstråle, Martin, Romano, Luciana, Rutters, Femke, Sharma, Sapna, Teare, Harriet, ‘t Hart, Leen, Tsirigos, Konstantinos D., Vangipurapu, Jagadish, Vestergaard, Henrik, Brunak, Søren, Franks, Paul W., Frost, Gary, Grallert, Harald, Jablonka, Bernd, McCarthy, Mark I., Pavo, Imre, Pedersen, Oluf, Ruetten, Hartmut, Walker, Mark, Adragni, Kofi, Allesøe, Rosa Lundbye L., Artati, Anna A., Arumugam, Manimozhiyan, Atabaki-Pasdar, Naeimeh, Baltauss, Tania, Banasik, Karina, Barnett, Anna L., Baum, Patrick, Bell, Jimmy D., Beulens, Joline W., Bianzano, Susanna B., Bizzotto, Roberto, Bonnefond, Amelie, Cabrelli, Louise, Dale, Matilda, Dawed, Adem Y., de Preville, Nathalie, Dekkers, Koen F., Deshmukh, Harshal A., Dings, Christiane, Donnelly, Louise, Dutta, Avirup, Ehrhardt, Beate, Engelbrechtsen, Line, Eriksen, Rebeca, Fan, Yong, Ferrer, Jorge, Fitipaldi, Hugo, Forman, Annemette, Fritsche, Andreas, Froguel, Philippe, Gassenhuber, Johann, Gough, Stephen, Graefe-Mody, Ulrike, Grempler, Rolf, Groeneveld, Lenka, Groop, Leif, Gudmundsdóttir, Valborg, Gupta, Ramneek, Hennige, Anita M.H., Hill, Anita V., Holl, Reinhard W., Hudson, Michelle, Jacobsen, Ulrik Plesner, Jennison, Christopher, Johansen, Joachim, Jonsson, Anna, Karaderi, Tugce, Kaye, Jane, Kennedy, Gwen, Klintenberg, Maria, Kuulasmaa, Teemu, Lehr, Thorsten, Loftus, Heather, Lundgaard, Agnete Troen T., Mazzoni, Gianluca, McRobert, Nicky, McVittie, Ian, Nice, Rachel, Nicolay, Claudia, Nijpels, Giel, Palmer, Colin N., Pedersen, Helle K., Perry, Mandy H., Pomares-Millan, Hugo, Prehn, Cornelia P., Ramisch, Anna, Rasmussen, Simon, Robertson, Neil, Rodriquez, Marianne, Sackett, Peter, Scherer, Nina, Shah, Nisha, Sihinevich, Iryna, Slieker, Roderick C., Sondertoft, Nadja B., Steckel-Hamann, Birgit, Thomas, Melissa K., Thomas, Cecilia Engel E., Thomas, Elizabeth Louise L., Thorand, Barbara, Thorne, Claire E., Tillner, Joachim, Tura, Andrea, Uhlen, Mathias, van Leeuwen, Nienke, van Oort, Sabine, Verkindt, Helene, Vogt, Josef, Wad Sackett, Peter W., Wesolowska-Andersen, Agata, Whitcher, Brandon, White, Margaret W., Adamski, Jerzy, Schwenk, Jochen M., Pearson, Ewan R., Dermitzakis, Emmanouil T., and Viñuela, Ana

Abstract

We evaluate the shared genetic regulation of mRNA molecules, proteins and metabolites derived from whole blood from 3029 human donors. We find abundant allelic heterogeneity, where multiple variants regulate a particular molecular phenotype, and pleiotropy, where a single variant associates with multiple molecular phenotypes over multiple genomic regions. The highest proportion of share genetic regulation is detected between gene expression and proteins (66.6%), with a further median shared genetic associations across 49 different tissues of 78.3% and 62.4% between plasma proteins and gene expression. We represent the genetic and molecular associations in networks including 2828 known GWAS variants, showing that GWAS variants are more often connected to gene expression in trans than other molecular phenotypes in the network. Our work provides a roadmap to understanding molecular networks and deriving the underlying mechanism of action of GWAS variants using different molecular phenotypes in an accessible tissue.

Published
2023

5. Glucagon‐like peptide ‐1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial

Author

Corbin, Karen D., primary, Carnero, Elvis A., additional, Allerton, Timothy D., additional, Tillner, Joachim, additional, Bock, Christopher P., additional, Luyet, Pierre‐Philippe, additional, Göbel, Britta, additional, Hall, Kevin D., additional, Parsons, Stephanie A., additional, Ravussin, Eric, additional, and Smith, Steven R., additional

Published
2023
Full Text
View/download PDF

6. Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes

Author

Eriksson, Olof, Velikyan, Irina, Haack, Torsten, Bossart, Martin, Laitinen, Iina, Larsen, Philip J., Berglund, Jan Erik, Antoni, Gunnar, Johansson, Lars, Pierrou, Stefan, Tillner, Joachim, Wagner, Michael, Eriksson, Olof, Velikyan, Irina, Haack, Torsten, Bossart, Martin, Laitinen, Iina, Larsen, Philip J., Berglund, Jan Erik, Antoni, Gunnar, Johansson, Lars, Pierrou, Stefan, Tillner, Joachim, and Wagner, Michael

Abstract

The glucagonlike peptide-1 receptor (GLP1R) is a gut hormone receptor, intricately linked to regulation of blood glucose homeostasis via several mechanisms. It is an established and emergent drug target in metabolic disease. The PET radioligand 68Ga-DO3A-VS-exendin4 (68Ga-exendin4) has the potential to enable longitudinal studies of GLP1R in the human pancreas. Methods: 68Ga-exendin4 PET/CT examinations were performed on overweight-to-obese individuals with type 2 diabetes (n = 13) as part of a larger target engagement study (NCT03350191). A scanning protocol was developed to optimize reproducibility (target amount of 0.5 MBq/kg [corresponding to peptide amount of <0.2 µg/kg], blood sampling, and tracer stability assessment). The pancreas and abdominal organs were segmented, and binding was correlated with clinical parameters. Results: Uptake of 68Ga-exendin4 in the pancreas, but not in other abdominal tissues, was high but variable between individuals. There was no evidence of self-blocking of GLP1R by the tracer in this protocol, despite the high potency of exendin4. The results showed that a full dynamic scan can be simplified to a short static scan, potentially increasing throughput and reducing patient discomfort. The 68Ga-exendin4 concentration in the pancreas (i.e., GLP1R density) correlated inversely with the age of the individual and tended to correlate positively with body mass index. However, the total GLP1R content in the pancreas did not. Conclusion: In summary, we present an optimized and simplified 68Ga-exendin4 scanning protocol to enable reproducible imaging of GLP1R in the pancreas. 68Ga-exendin4 PET may enable quantification of longitudinal changes in pancreatic GLP1R during the development of type 2 diabetes, as well as target engagement studies of novel glucagonlike peptide-1 agonists.

Published
2022
Full Text
View/download PDF

8. Glucagon Like Peptide-1 receptor imaging in individuals with Type 2 Diabetes

Author

Eriksson, Olof, primary, Velikyan, Irina, additional, Haack, Torsten, additional, Bossart, Martin, additional, Laitinen, Iina, additional, Larsen, Philip Just, additional, Berglund, Jan Erik, additional, Antoni, Gunnar, additional, Johansson, Lars, additional, Pierrou, Stefan, additional, Tillner, Joachim, additional, and Wagner, Michael, additional

Published
2021
Full Text
View/download PDF

9. Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes

Author

Eriksson, Olof, Velikyan, Irina, Haack, Torsten, Bossart, Martin, Laitinen, Iina, Larsen, Philip J., Berglund, Jan Erik, Antoni, Gunnar, Johansson, Lars, Pierrou, Stefan, Tillner, Joachim, Wagner, Michael, Eriksson, Olof, Velikyan, Irina, Haack, Torsten, Bossart, Martin, Laitinen, Iina, Larsen, Philip J., Berglund, Jan Erik, Antoni, Gunnar, Johansson, Lars, Pierrou, Stefan, Tillner, Joachim, and Wagner, Michael

Abstract

Despite the importance of the glucagon receptor (GCGR) in disease and in pharmaceutical drug development, there is a lack of specific and sensitive biomarkers of its activation in humans. The PET radioligand Ga-68-DO3A-VS-Tuna-2 (Ga-68-Tuna-2) was developed to yield a noninvasive imaging marker for GCGR target distribution and drug target engagement in humans. Methods: The biodistribution and dosimetry of Ga-68-Tuna-2 was assessed by PET/CT in 13 individuals with type 2 diabetes as part of a clinical study assessing the occupancy of the dual GCGR/glucagon like peptide-1 receptor agonist SAR425899. Binding of Ga-68-Tuna-2 in liver and reference tissues was evaluated and correlated to biometrics (e.g., weight or body mass index) or other biomarkers (e.g., plasma glucagon levels). Results: Ga-68-Tuna-2 binding was seen primarily in the liver, which is in line with the strong expression of GCGR on hepatocytes. The kidneys demonstrated high excretion-related retention, whereas all other tissue demonstrated rapid washout. The SUV55 (min) (SUV during the last 10-min time frame, 50-60 min after administration) uptake endpoint was sensitive to endogenous levels of glucagon. Ga-68-Tuna-2 exhibited a safe dosimetry profile and no adverse events after intravenous administration. Conclusion: Ga-68-Tuna-2 can be used for safe and accurate assessment of the GCGR in human. It may serve as an important tool in understanding the in vivo pharmacology of novel drugs engaging the GCGR.

Published
2021
Full Text
View/download PDF

10. A Metabolomic Signature of Glucagon Action in Healthy Individuals With Overweight/Obesity

Author

Vega, Rick B, primary, Whytock, Katie L, additional, Gassenhuber, Johan, additional, Goebel, Britta, additional, Tillner, Joachim, additional, Agueusop, Inoncent, additional, Truax, Agnieszka D, additional, Yu, Gongxin, additional, Carnero, Elvis, additional, Kapoor, Nidhi, additional, Gardell, Stephen, additional, Sparks, Lauren M, additional, and Smith, Steven R, additional

Published
2021
Full Text
View/download PDF

12. Automated GMP-Compliant Production of [Ga-68]Ga-DO3A-Tuna-2 for PET Microdosing Studies of the Glucagon Receptor in Humans

Author

Wagner, Michael, Doverfjord, Johan G., Tillner, Joachim, Antoni, Gunnar, Haack, Torsten, Bossart, Martin, Laitinen, Iina, Johansson, Lars, Pierrou, Stefan, Eriksson, Olof, Velikyan, Irina, Wagner, Michael, Doverfjord, Johan G., Tillner, Joachim, Antoni, Gunnar, Haack, Torsten, Bossart, Martin, Laitinen, Iina, Johansson, Lars, Pierrou, Stefan, Eriksson, Olof, and Velikyan, Irina

Abstract

Introduction: [Ga-68]Ga-DO3A-VS-Cys(40)-Tuna-2 (previously published as [Ga-68]Ga-DO3A-VS-Cys(40)-S01-GCG) has shown high-affinity specific binding to the glucagon receptor (GCGR) in vitro and in vivo in rats and non-human primates in our previous studies, confirming the suitability of the tracer for drug development applications in humans. The manufacturing process of [Ga-68]Ga-DO3A-VS-Cys(40)-Tuna-2 was automated for clinical use to meet the radiation safety and good manufacturing practice (GMP) requirements.Methods:The automated synthesis platform (Modular-Lab PharmTrace, Eckert & Ziegler, Eurotope, Germany), disposable cassettes for(68)Ga-labeling, and pharmaceutical-grade(68)Ge/Ga-68 generator (GalliaPharm(R)) used in the study were purchased from Eckert & Ziegler. The parameters such as time, temperature, precursor concentration, radical scavenger, buffer concentration, and pH, as well as product purification step, were investigated and optimized. Process optimization was conducted with regard to product quality and quantity, as well as process reproducibility. The active pharmaceutical ingredient starting material DO3A-VS-Cys(40)-Tuna-2 (GMP-grade) was provided by Sanofi Aventis.Results:The reproducible and GMP-compliant automated production of [Ga-68]Ga-DO3A-VS-Cys(40)-Tuna-2 with on-line documentation was developed. The non-decay-corrected radiochemical yield was 45.2 +/- 2.5% (n= 3, process validation) at the end of the synthesis with a labeling synthesis duration of 38 min and a quality controlincluding release procedure of 20 min. The radiochemical purity of the product was 98.9 +/- 0.6% (n= 17) with the total amount of the peptide in the preparation of 48 +/- 2 mu g (n= 3, process validation). Radionuclidic purity, sterility, endotoxin content, residual solvent content, and sterile filter integrity tests met the acceptance criteria. The product was stable at ambient temperature for at least 2 h.Conclusion:The fully automated GMP-compliant manufa

Published
2020
Full Text
View/download PDF

14. Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes

Author

Eriksson, Olof, primary, Velikyan, Irina, additional, Haack, Torsten, additional, Bossart, Martin, additional, Laitinen, Iina, additional, Larsen, Philip J., additional, Berglund, Jan Erik, additional, Antoni, Gunnar, additional, Johansson, Lars, additional, Pierrou, Stefan, additional, Tillner, Joachim, additional, and Wagner, Michael, additional

Published
2020
Full Text
View/download PDF

16. Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration

Author

Wilman, Henry R., Parisinos, Constantinos A., Atabaki-Pasdar, Naeimeh, Kelly, Matt, Thomas, E. Louise, Neubauer, Stefan, Jennison, Christopher, Ehrhardt, Beate, Baum, Patrick, Schoelsch, Corinna, Freijer, Jan, Grempler, Rolf, Graefe-Mody, Ulrike, Hennige, Anita, Dings, Christiane, Lehr, Thorsten, Scherer, Nina, Sihinecich, Iryna, Pattou, Francois, Raverdi, Violeta, Caiazzo, Robert, Torres, Fanelly, Verkindt, Helene, Mari, Andrea, Tura, Andrea, Giorgino, Toni, Bizzotto, Roberto, Froguel, Philippe, Bonneford, Amelie, Canouil, Mickael, Dhennin, Veronique, Brorsson, Caroline, Brunak, Soren, De Masi, Federico, Gudmundsdóttir, Valborg, Pedersen, Helle, Banasik, Karina, Thomas, Cecilia, Sackett, Peter, Staerfeldt, Hans Henrik, Lundgaard, Agnete, Nilsson, Birgitte, Nielsen, Agnes, Mazzoni, Gianluca, Karaderi, Tugce, Rasmussen, Simon, Johansen, Joachim, Allesøe, Rosa, Fritsche, Andreas, Thorand, Barbara, Adamski, Jurek, Grallert, Harald, Haid, Mark, Sharma, Sapna, Troll, Martina, Adam, Jonathan, Ferrer, Jorge, Eriksen, Heather, Frost, Gary, Haussler, Ragna, Hong, Mun gwan, Schwenk, Jochen, Uhlen, Mathias, Nicolay, Claudia, Pavo, Imre, Steckel-Hamann, Birgit, Thomas, Melissa, Adragni, Kofi, Wu, Han, Hart, Leen't, Roderick, Slieker, van Leeuwen, Nienke, Dekkers, Koen, Frau, Francesca, Gassenhuber, Johann, Jablonka, Bernd, Musholt, Petra, Ruetten, Hartmut, Tillner, Joachim, Baltauss, Tania, Bernard Poenaru, Oana, de Preville, Nathalie, Rodriquez, Marianne, Arumugam, Manimozhiyan, Allin, Kristine, Engelbrechtsen, Line, Hansen, Torben, Hansen, Tue, Forman, Annemette, Jonsson, Anna, Pedersen, Oluf, Dutta, Avirup, Vogt, Josef, Vestergaard, Henrik, Laakso, Markku, Kokkola, Tarja, Kuulasmaa, Teemu, Franks, Paul, Giordano, Nick, and Pomares-Millan, Hugo

Subjects
Genome-wide association study, Magnetic resonance imaging, Metabolism, Iron, Genetics, Metabolic syndrome
Abstract

Background & Aims: Excess liver iron content is common and is linked to the risk of hepatic and extrahepatic diseases. We aimed to identify genetic variants influencing liver iron content and use genetics to understand its link to other traits and diseases. Methods: First, we performed a genome-wide association study (GWAS) in 8,289 individuals from UK Biobank, whose liver iron level had been quantified by magnetic resonance imaging, before validating our findings in an independent cohort (n = 1,513 from IMI DIRECT). Second, we used Mendelian randomisation to test the causal effects of 25 predominantly metabolic traits on liver iron content. Third, we tested phenome-wide associations between liver iron variants and 770 traits and disease outcomes. Results: We identified 3 independent genetic variants (rs1800562 [C282Y] and rs1799945 [H63D] in HFE and rs855791 [V736A] in TMPRSS6) associated with liver iron content that reached the GWAS significance threshold (p

Published
2019
Full Text
View/download PDF

18. Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration

Author

Wilman, Henry R., primary, Parisinos, Constantinos A., additional, Atabaki-Pasdar, Naeimeh, additional, Kelly, Matt, additional, Thomas, E. Louise, additional, Neubauer, Stefan, additional, Mahajan, Anubha, additional, Hingorani, Aroon D., additional, Patel, Riyaz S., additional, Hemingway, Harry, additional, Franks, Paul W., additional, Bell, Jimmy D., additional, Banerjee, Rajarshi, additional, Yaghootkar, Hanieh, additional, Jennison, Christopher, additional, Ehrhardt, Beate, additional, Baum, Patrick, additional, Schoelsch, Corinna, additional, Freijer, Jan, additional, Grempler, Rolf, additional, Graefe-Mody, Ulrike, additional, Hennige, Anita, additional, Dings, Christiane, additional, Lehr, Thorsten, additional, Scherer, Nina, additional, Sihinecich, Iryna, additional, Pattou, Francois, additional, Raverdi, Violeta, additional, Caiazzo, Robert, additional, Torres, Fanelly, additional, Verkindt, Helene, additional, Mari, Andrea, additional, Tura, Andrea, additional, Giorgino, Toni, additional, Bizzotto, Roberto, additional, Froguel, Philippe, additional, Bonneford, Amelie, additional, Canouil, Mickael, additional, Dhennin, Veronique, additional, Brorsson, Caroline, additional, Brunak, Soren, additional, De Masi, Federico, additional, Gudmundsdóttir, Valborg, additional, Pedersen, Helle, additional, Banasik, Karina, additional, Thomas, Cecilia, additional, Sackett, Peter, additional, Staerfeldt, Hans-Henrik, additional, Lundgaard, Agnete, additional, Nilsson, Birgitte, additional, Nielsen, Agnes, additional, Mazzoni, Gianluca, additional, Karaderi, Tugce, additional, Rasmussen, Simon, additional, Johansen, Joachim, additional, Allesøe, Rosa, additional, Fritsche, Andreas, additional, Thorand, Barbara, additional, Adamski, Jurek, additional, Grallert, Harald, additional, Haid, Mark, additional, Sharma, Sapna, additional, Troll, Martina, additional, Adam, Jonathan, additional, Ferrer, Jorge, additional, Eriksen, Heather, additional, Frost, Gary, additional, Haussler, Ragna, additional, Hong, Mun-gwan, additional, Schwenk, Jochen, additional, Uhlen, Mathias, additional, Nicolay, Claudia, additional, Pavo, Imre, additional, Steckel-Hamann, Birgit, additional, Thomas, Melissa, additional, Adragni, Kofi, additional, Wu, Han, additional, Hart, Leen't, additional, Roderick, Slieker, additional, van Leeuwen, Nienke, additional, Dekkers, Koen, additional, Frau, Francesca, additional, Gassenhuber, Johann, additional, Jablonka, Bernd, additional, Musholt, Petra, additional, Ruetten, Hartmut, additional, Tillner, Joachim, additional, Baltauss, Tania, additional, Bernard Poenaru, Oana, additional, de Preville, Nathalie, additional, Rodriquez, Marianne, additional, Arumugam, Manimozhiyan, additional, Allin, Kristine, additional, Engelbrechtsen, Line, additional, Hansen, Torben, additional, Hansen, Tue, additional, Forman, Annemette, additional, Jonsson, Anna, additional, Pedersen, Oluf, additional, Dutta, Avirup, additional, Vogt, Josef, additional, Vestergaard, Henrik, additional, Laakso, Markku, additional, Kokkola, Tarja, additional, Kuulasmaa, Teemu, additional, Franks, Paul, additional, Giordano, Nick, additional, Pomares-Millan, Hugo, additional, Fitipaldi, Hugo, additional, Mutie, Pascal, additional, Klintenberg, Maria, additional, Bergstrom, Margit, additional, Groop, Leif, additional, Ridderstrale, Martin, additional, Atabaki Pasdar, Naeimeh, additional, Deshmukh, Harshal, additional, Heggie, Alison, additional, Wake, Dianne, additional, McEvoy, Donna, additional, McVittie, Ian, additional, Walker, Mark, additional, Hattersley, Andrew, additional, Hill, Anita, additional, Jones, Angus, additional, McDonald, Timothy, additional, Perry, Mandy, additional, Nice, Rachel, additional, Hudson, Michelle, additional, Thorne, Claire, additional, Dermitzakis, Emmanouil, additional, Viñuela, Ana, additional, Cabrelli, Louise, additional, Loftus, Heather, additional, Dawed, Adem, additional, Donnelly, Louise, additional, Forgie, Ian, additional, Pearson, Ewan, additional, Palmer, Colin, additional, Brown, Andrew, additional, Koivula, Robert, additional, Wesolowska-Andersen, Agata, additional, Abdalla, Moustafa, additional, McRobert, Nicky, additional, Fernandez, Juan, additional, Jiao, Yunlong, additional, Robertson, Neil, additional, Gough, Stephen, additional, Kaye, Jane, additional, Mourby, Miranda, additional, McCarthy, Mark, additional, Shah, Nisha, additional, Teare, Harriet, additional, Holl, Reinhard, additional, Koopman, Anitra, additional, Rutters, Femke, additional, Beulens, Joline, additional, Groeneveld, Lenka, additional, Bell, Jimmy, additional, Thomas, Louise, additional, and Whitcher, Brandon, additional

Published
2019
Full Text
View/download PDF

19. A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials

Author

Tillner, Joachim, primary, Posch, Maximilian G., additional, Wagner, Frank, additional, Teichert, Lenore, additional, Hijazi, Youssef, additional, Einig, Christine, additional, Keil, Stefanie, additional, Haack, Torsten, additional, Wagner, Michael, additional, Bossart, Martin, additional, and Larsen, Philip J., additional

Published
2018
Full Text
View/download PDF

20. A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials.

Author

Tillner, Joachim, Posch, Maximilian G., Wagner, Frank, Teichert, Lenore, Hijazi, Youssef, Einig, Christine, Keil, Stefanie, Haack, Torsten, Wagner, Michael, Bossart, Martin, and Larsen, Philip J.

Subjects
*GLUCAGON-like peptide 1, *PHARMACOKINETICS, *POLYPEPTIDES, *OVERWEIGHT persons, *BODY mass index
Abstract

Aims: To evaluate the safety, pharmacokinetics and pharmacodynamics of SAR425899, a novel polypeptide, active as an agonist at both the glucagon‐like peptide‐1 receptor (GLP‐1R) and the glucagon receptor (GCR), in healthy volunteers and in overweight/obese patients with type 2 diabetes (T2D). Methods: Subcutaneous administrations of SAR425899 were tested in two randomized, placebo‐controlled, double‐blind clinical trials. In the first trial, healthy overweight volunteers (body mass index [BMI] 25‐30 kg/m2; n = 32) received single‐ascending doses (0.01‐0.1 mg) of SAR425899 or placebo. In the second, a multiple‐ascending‐dose trial (NCT02411825), healthy normal‐ to overweight volunteers (BMI 20‐30 kg/m2; n = 40) and overweight/obese patients with T2D (BMI 28‐42 kg/m2; n = 36) received daily doses of SAR425899 or placebo over 21 or 28 days, respectively. Results: The most frequently reported adverse events were gastrointestinal; gastrointestinal side effects were less pronounced in patients with T2D compared with healthy volunteers. SAR425899 significantly reduced levels of fasting plasma glucose (P < 0.05 vs. placebo) and glycated haemoglobin (P < 0.001 versus placebo) in patients with T2D. Additionally, SAR425899 led to reductions in body weight, with a maximal reduction of 5.32 kg in healthy volunteers and 5.46 kg in patients with T2D (P < 0.001 vs. placebo) at end of treatment. Conclusions: SAR425899 was well tolerated and led to favourable glycaemic effects in patients with T2D and weight reduction in both healthy volunteers and patients. Whether dual GLP‐1R/GCR agonism represents a treatment method that is superior to pure GLP‐1R agonists for obesity and diabetes treatment remains to be confirmed. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

22. EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study.

Author

Mamo, David, Sedman, Ewen, Tillner, Joachim, Sellers, Edward M., Romach, Myroslava K., and Kapur, Shitij

Subjects
SEROTONIN, DRUGS, CEREBRAL cortex, NEUROTRANSMITTERS, NEUROPSYCHIATRY
Abstract

While serotonin 5HT2-receptors have been implicated in the etiology and pharmacological treatment of a number of neuropsychiatric conditions, there are few potent and specific agents available for use in human clinical studies. EMD 281014 is a highly specific 5HT2-receptor antagonist that is currently under development. To find optimal doses for early clinical studies, we conducted a PET study using [18F]setoperone in nine healthy subjects scanned at baseline and following the administration of 1, 3, and 7 mg EMD 281014. The study drug was well tolerated by all study participants, and all doses resulted in =70% occupancy at frontal 5HT2-receptors 3 h after drug administration. The data suggest that daily dosing of =3 mg EMD 281014 should be sufficient to provide sustained high levels of 5HT2-receptor occupancy in future clinical trials. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

23. Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes.

Author

Eriksson O, Velikyan I, Haack T, Bossart M, Laitinen I, Larsen PJ, Berglund JE, Antoni G, Johansson L, Pierrou S, Tillner J, and Wagner M

Subjects
Gallium Radioisotopes, Humans, Peptides chemistry, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography methods, Reproducibility of Results, Diabetes Mellitus, Type 2 diagnostic imaging, Glucagon-Like Peptide-1 Receptor metabolism
Abstract

The glucagonlike peptide-1 receptor (GLP1R) is a gut hormone receptor, intricately linked to regulation of blood glucose homeostasis via several mechanisms. It is an established and emergent drug target in metabolic disease. The PET radioligand 68 Ga-DO3A-VS-exendin4 ( 68 Ga-exendin4) has the potential to enable longitudinal studies of GLP1R in the human pancreas. Methods: 68 Ga-exendin4 PET/CT examinations were performed on overweight-to-obese individuals with type 2 diabetes ( n  = 13) as part of a larger target engagement study (NCT03350191). A scanning protocol was developed to optimize reproducibility (target amount of 0.5 MBq/kg [corresponding to peptide amount of <0.2 µg/kg], blood sampling, and tracer stability assessment). The pancreas and abdominal organs were segmented, and binding was correlated with clinical parameters. Results: Uptake of 68 Ga-exendin4 in the pancreas, but not in other abdominal tissues, was high but variable between individuals. There was no evidence of self-blocking of GLP1R by the tracer in this protocol, despite the high potency of exendin4. The results showed that a full dynamic scan can be simplified to a short static scan, potentially increasing throughput and reducing patient discomfort. The 68 Ga-exendin4 concentration in the pancreas (i.e., GLP1R density) correlated inversely with the age of the individual and tended to correlate positively with body mass index. However, the total GLP1R content in the pancreas did not. Conclusion: In summary, we present an optimized and simplified 68 Ga-exendin4 scanning protocol to enable reproducible imaging of GLP1R in the pancreas. 68 Ga-exendin4 PET may enable quantification of longitudinal changes in pancreatic GLP1R during the development of type 2 diabetes, as well as target engagement studies of novel glucagonlike peptide-1 agonists., (© 2022 by the Society of Nuclear Medicine and Molecular Imaging.)

Published
2022
Full Text
View/download PDF

24. Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes.

Author

Eriksson O, Velikyan I, Haack T, Bossart M, Laitinen I, Larsen PJ, Berglund JE, Antoni G, Johansson L, Pierrou S, Tillner J, and Wagner M

Subjects
Adult, Body Weight, Female, Gallium Radioisotopes, Humans, Kidney metabolism, Male, Positron Emission Tomography Computed Tomography, Radiometry, Tissue Distribution, Diabetes Mellitus, Type 2 diagnostic imaging, Diabetes Mellitus, Type 2 metabolism, Receptors, Glucagon metabolism
Abstract

Despite the importance of the glucagon receptor (GCGR) in disease and in pharmaceutical drug development, there is a lack of specific and sensitive biomarkers of its activation in humans. The PET radioligand 68 Ga-DO3A-VS-Tuna-2 ( 68 Ga-Tuna-2) was developed to yield a noninvasive imaging marker for GCGR target distribution and drug target engagement in humans. Methods: The biodistribution and dosimetry of 68 Ga-Tuna-2 was assessed by PET/CT in 13 individuals with type 2 diabetes as part of a clinical study assessing the occupancy of the dual GCGR/glucagon like peptide-1 receptor agonist SAR425899. Binding of 68 Ga-Tuna-2 in liver and reference tissues was evaluated and correlated to biometrics (e.g., weight or body mass index) or other biomarkers (e.g., plasma glucagon levels). Results: 68 Ga-Tuna-2 binding was seen primarily in the liver, which is in line with the strong expression of GCGR on hepatocytes. The kidneys demonstrated high excretion-related retention, whereas all other tissue demonstrated rapid washout. The SUV 55 min (SUV during the last 10-min time frame, 50-60 min after administration) uptake endpoint was sensitive to endogenous levels of glucagon. 68 Ga-Tuna-2 exhibited a safe dosimetry profile and no adverse events after intravenous administration. Conclusion: 68 Ga-Tuna-2 can be used for safe and accurate assessment of the GCGR in human. It may serve as an important tool in understanding the in vivo pharmacology of novel drugs engaging the GCGR., (© 2021 by the Society of Nuclear Medicine and Molecular Imaging.)

Published
2021
Full Text
View/download PDF

25. Automated GMP-Compliant Production of [ 68 Ga]Ga-DO3A-Tuna-2 for PET Microdosing Studies of the Glucagon Receptor in Humans.

Author

Wagner M, Doverfjord JG, Tillner J, Antoni G, Haack T, Bossart M, Laitinen I, Johansson L, Pierrou S, Eriksson O, and Velikyan I

Abstract

Introduction : [ 68 Ga]Ga-DO3A-VS-Cys 40 -Tuna-2 (previously published as [ 68 Ga]Ga-DO3A-VS-Cys 40 -S01-GCG) has shown high-affinity specific binding to the glucagon receptor (GCGR) in vitro and in vivo in rats and non-human primates in our previous studies, confirming the suitability of the tracer for drug development applications in humans. The manufacturing process of [ 68 Ga]Ga-DO3A-VS-Cys 40 -Tuna-2 was automated for clinical use to meet the radiation safety and good manufacturing practice (GMP) requirements. Methods: The automated synthesis platform (Modular-Lab PharmTrace, Eckert & Ziegler, Eurotope, Germany), disposable cassettes for 68 Ga-labeling, and pharmaceutical-grade 68 Ge/ 68 Ga generator (GalliaPharm ® ) used in the study were purchased from Eckert & Ziegler. The parameters such as time, temperature, precursor concentration, radical scavenger, buffer concentration, and pH, as well as product purification step, were investigated and optimized. Process optimization was conducted with regard to product quality and quantity, as well as process reproducibility. The active pharmaceutical ingredient starting material DO3A-VS-Cys 40 -Tuna-2 (GMP-grade) was provided by Sanofi Aventis. Results: The reproducible and GMP-compliant automated production of [ 68 Ga]Ga-DO3A-VS-Cys 40 -Tuna-2 with on-line documentation was developed. The non-decay-corrected radiochemical yield was 45.2 ± 2.5% ( n = 3, process validation) at the end of the synthesis with a labeling synthesis duration of 38 min and a quality controlincluding release procedure of 20 min. The radiochemical purity of the product was 98.9 ± 0.6% ( n = 17) with the total amount of the peptide in the preparation of 48 ± 2 µg ( n = 3, process validation). Radionuclidic purity, sterility, endotoxin content, residual solvent content, and sterile filter integrity tests met the acceptance criteria. The product was stable at ambient temperature for at least 2 h. Conclusion: The fully automated GMP-compliant manufacturing process was developed and thoroughly validated. The resulting [ 68 Ga]Ga-DO3A-VS-Cys 40 -Tuna-2 was used in a clinical study for accurate quantification of GCGR occupancy by a dual anti-diabetic drug in vivo in humans.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results